Clarus Therapeutics (NASDAQ:CRXT – Get Rating) had its price target lowered by investment analysts at Maxim Group to $1.50 in a research note issued to investors on Thursday, Stock Target Advisor reports. Maxim Group’s price objective would suggest a potential upside of 284.52% from the company’s current price.
A number of other equities research analysts also recently weighed in on CRXT. Truist Financial cut their target price on Clarus Therapeutics from $7.00 to $3.00 and set a “na” rating for the company in a research report on Tuesday, May 17th. Needham & Company LLC cut their price objective on Clarus Therapeutics to $3.00 and set a “buy” rating for the company in a report on Tuesday, May 17th. Finally, Zacks Investment Research raised Clarus Therapeutics from a “hold” rating to a “buy” rating and set a $1.75 target price on the stock in a report on Monday, April 4th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $6.88.
Clarus Therapeutics stock traded up $0.02 during mid-day trading on Thursday, hitting $0.39. 185,348 shares of the company’s stock traded hands, compared to its average volume of 8,450,540. Clarus Therapeutics has a one year low of $0.35 and a one year high of $31.24. The firm has a 50 day moving average price of $1.00 and a 200 day moving average price of $2.00.
Several institutional investors have recently made changes to their positions in the company. Powell Investment Advisors LLC lifted its holdings in shares of Clarus Therapeutics by 48.8% during the fourth quarter. Powell Investment Advisors LLC now owns 64,000 shares of the company’s stock valued at $156,000 after purchasing an additional 21,000 shares during the last quarter. Telemetry Investments L.L.C. acquired a new stake in Clarus Therapeutics during the 3rd quarter worth about $240,000. UBS Group AG purchased a new stake in Clarus Therapeutics during the third quarter valued at about $206,000. Renaissance Technologies LLC acquired a new position in shares of Clarus Therapeutics in the first quarter worth about $52,000. Finally, Schonfeld Strategic Advisors LLC purchased a new position in shares of Clarus Therapeutics in the fourth quarter worth approximately $51,000. 19.50% of the stock is currently owned by institutional investors.
About Clarus Therapeutics (Get Rating)
Clarus Therapeutics Holdings, Inc, a pharmaceutical company, focuses on the development and commercialization of oral testosterone replacement therapy in the United States. It offers JATENZO, a soft gel oral formulation of testosterone undecanoate for treating hypogonadal men. The company has a licensing agreement with HavaH Therapeutics for product to treat androgen therapies for inflammatory breast disease and certain forms of breast cancer; and license agreement with The Royal Institution for the Advancement of Learning/McGill University to develop and commercialize McGill's proprietary technology designed to treat conditions associated with CoQ10 deficiencies in humans.
- Get a free copy of the StockNews.com research report on Clarus Therapeutics (CRXT)
- Genesco Pops On Earnings But Don’t Expect A Rally
- The Insiders Are Selling Movado Group, But You Shouldn’t
- Beware The Rebound In Retail Stocks
- It’s A Good Time To Own Ralph Lauren (NYSE: RL)
- Block, Inc: Correcting for Negative Earnings
Receive News & Ratings for Clarus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clarus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.